Protective effect of a polyvalent influenza DNA vaccine in pigs by Karlsson, Ingrid et al.
Contents lists available at ScienceDirect
Veterinary Immunology and Immunopathology
journal homepage: www.elsevier.com/locate/vetimm
Protective eﬀect of a polyvalent inﬂuenza DNA vaccine in pigs
Ingrid Karlssona,1, Marie Borggrena,1, Maiken Worsøe Rosenstiernea, Ramona Trebbienb,
James A. Williamsc, Enric Vidald, Júlia Vergara-Alertd, David Solanes Fozd, Ayub Darjid,
Marta Sisteré-Oród, Joaquim Segalése,f, Jens Nielsena,2, Anders Fomsgaarda,g,2,⁎
a Virus Research and Development Laboratory, Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S,
Denmark
bNational Inﬂuenza Center Denmark, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
cNature Technology Corporation, 4701 Innovation Dr, Lincoln, NE 68521, USA
d IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
eUAB, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
fDepartament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Spain
g Infectious Disease Research Unit, Clinical Institute, University of Southern Denmark, Sdr. Boulevard 29, DK-5000 Odense C, Denmark
A R T I C L E I N F O
Keywords:
Challenge
DNA vaccine
H1N1pdm09
Needle-free immunization
Protection
Swine inﬂuenza
A B S T R A C T
Background: Inﬂuenza A virus in swine herds represents a major problem for the swine industry and poses a
constant threat for the emergence of novel pandemic viruses and the development of more eﬀective inﬂuenza
vaccines for pigs is desired. By optimizing the vector backbone and using a needle-free delivery method, we have
recently demonstrated a polyvalent inﬂuenza DNA vaccine that induces a broad immune response, including
both humoral and cellular immunity.
Objectives: To investigate the protection of our polyvalent inﬂuenza DNA vaccine approach in a pig challenge
study.
Methods: By intradermal needle-free delivery to the skin, we immunized pigs with two diﬀerent doses (500 μg
and 800 μg) of an inﬂuenza DNA vaccine based on six genes of pandemic origin, including internally expressed
matrix and nucleoprotein and externally expressed hemagglutinin and neuraminidase as previously demon-
strated. Two weeks following immunization, the pigs were challenged with the 2009 pandemic H1N1 virus.
Results: When challenged with 2009 pandemic H1N1, 0/5 vaccinated pigs (800 μg DNA) became infected
whereas 5/5 unvaccinated control pigs were infected. The pigs vaccinated with the low dose (500 μg DNA) were
only partially protected. The DNA vaccine elicited binding-, hemagglutination inhibitory (HI)− as well as cross-
reactive neutralizing antibody activity and neuraminidase inhibiting antibodies in the immunized pigs, in a dose-
dependent manner.
Conclusion: The present data, together with the previously demonstrated immunogenicity of our inﬂuenza DNA
vaccine, indicate that naked DNA vaccine technology provides a strong approach for the development of im-
proved pig vaccines, applying realistic low doses of DNA and a convenient delivery method for mass vaccination.
1. Introduction
Inﬂuenza A virus infections in swine herds constitute a well-known
challenge to the swine industry. Reproductive problems together with
weight loss and aggravation of secondary infections are characteristic of
swine inﬂuenza and result in serious animal welfare problems and
economic losses (Bennett et al., 1999; Olsen et al., 2006). The inﬂuenza
infection in pigs resembles the infection in humans. The virus replicates
in the epithelium of the entire respiratory tract but rarely infects other
tissues (van der Laan et al., 2008). The disease lasts for 7–10 days
seldom results in death of the animals (van der Laan et al., 2008). In
addition, the tremendous genetic plasticity of the virus can result in
transmission between animals as well as zoonotic transmission and
adaptation to human hosts, resulting in novel pandemic inﬂuenza
strains such as the pandemic 2009 H1N1 strain (Ito et al., 1998; Nelson
and Vincent, 2015; Smith et al., 2009). A successful, more broadly
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protective vaccine for pigs against inﬂuenza A virus is very much de-
sired, since it will improve the health in pig herds, limit the use of
antibiotics and lower the risk of transmission to other species, such as
humans. The current vaccines against inﬂuenza A virus for pigs are
based on inactivated virus and only induce immunity against the virus
strains included in the vaccines, thus providing only limited protection
against the diverse spectrum of other circulating inﬂuenza strains
(Sandbulte et al., 2015). DNA vaccine technology is already approved
for use in pigs (Thacker et al., 2006) and has many advantages required
for an eﬀective inﬂuenza vaccine, such as rapid production, easy
plasmid modiﬁcation, a stable formulation and in vivo antigen expres-
sion leading to induction of both broad and long-lived cellular and
humoral immunity (Kutzler and Weiner, 2008; Li and Petrovsky, 2015;
Liu, 2011). The technique has previously been tested by us and others
in pigs against inﬂuenza (Bragstad et al., 2013; Eriksson et al., 1998;
Gorres et al., 2011; Heinen et al., 2002; Larsen et al., 2001; Macklin
et al., 1998; Olsen, 2000). Several optimizations can be applied today to
improve the production and immunogenicity of the vaccines. We and
others have described improvements of inﬂuenza DNA vaccines, in-
cluding optimizing the plasmid vector backbone (Borggren et al., 2015;
Williams, 2013). and delivery of the vaccine intradermally with a
convenient needle-free device developed for mass vaccination
(Borggren et al., 2015; Martelli et al., 2007).
Recently, we reported a broad immune response induced in pigs by
a DNA vaccine in vivo expressing six diﬀerent genes of pandemic viral
origin (Borggren et al., 2016, 2015). The pandemic nature of the DNA
genes makes them the ancestor of all subsequent strains and are natu-
rally less glycosylated when expressed in vivo, compared to circulating
virus strains with more glycosylation acquired by antigenic drift
(Sriwilaijaroen and Suzuki, 2012; Wang et al., 2009; Wei et al., 2010).
Consequently, a broader range of epitopes can be recognized by the
DNA vaccine-induced response, thus producing a more cross-reactive
immunity. Thus, our DNA vaccine induced both humoral and cellular
immunity against virus strains homologous and heterologous to the
DNA vaccine genes (Borggren et al., 2016). In the present study, we
have evaluated the immunogenicity, dose-response, and protective ef-
fect of the same polyvalent DNA vaccine in an inﬂuenza-virus challenge
study in pigs.
2. Materials and methods
2.1. Construction of DNA vaccines
The six inﬂuenza DNA vaccine genes have been described pre-
viously (Borggren et al., 2016, 2015). Brieﬂy, the 6 inﬂuenza DNA
vaccine genes were designed from nucleotide sequences published in
GenBank derived from only pandemic inﬂuenza strains; 1918 NP: A/
Brevig Mission/1/18(H1N1), 1918 M: A/Brevig Mission/1/18(H1N1),
2009 HA: A/California/04/2009(H1N1)pdm09, 2009 NA: A/Cali-
fornia/04/2009(H1N1)pdm09, 1968 HA: A/Aichi/2/1968(H3N2),
1968 NA: A/Aichi/2/1968(H3N2). The genes were synthesized and
designed to include the appropriate restriction enzymes and the Kozak-
sequence (GCCACC) upstream from the start codon, for eﬃcient cloning
and transcription into the expression vector. All genes were synthesized
using only codons from highly expressed human or mammalian genes
(codon optimized), except the M gene that was not codon optimized.
The minimal NTC9385R plasmid, free of antibiotic resistance genes,
was used as the expression vector backbone (Williams, 2013).
2.2. Animals and experimental design
Fifteen 5-to-6-week-old, recently weaned male pigs (Yorkshire x
Landrace breed), tested inﬂuenza-negative by ID Screen® Inﬂuenza A
Antibody Competition Multi-species ELISA (ID.VET, France), were
procured from a commercial Spanish high-health herd free from
Porcine Respiratory and Reproductive Syndrome (PRRS), Aujeszky’s
disease, Pasteurella multocida and Brachyspira spp., but positive for
Haemophilus parasuis, Mycoplasma hyopneumoniae and Actinobacillus
pleuropneumoniae serotype 2. Prior to weaning, the pigs had been vac-
cinated against porcine circovirus type 2 (PCV2) and Mycoplasma
hyopneumoniae. The pigs were randomly assigned to three groups of ﬁve
animals (two vaccinated groups allocated in one box and one non-
vaccinated group in another one). Boxes were subjected to negative
pressure at the biosafety level 3 isolation facilities of the Centre de
Recerca en Sanitat Animal (CReSA), Institut de Recerca i Tecnologia
Agroalimentàries (IRTA), Spain. Pigs were allowed to acclimatize for
one week before the initiation of the experiment.
With an interval of three weeks, two groups of pigs were vaccinated
twice on the dorsal side of the back using the needle-free Intra-Dermal
Application of Liquids (IDAL® MSD Animal Health) device (Ferrari
et al., 2011; Visser et al., 1994). For use of the IDAL® device, the vaccine
constructs were premixed at a 1:1 vol ratio with an α-tocopherol-based
aqueous solution (Diluvac Forte®, MSD Animal Health) (Borggren et al.,
2016, 2015). Five pigs were immunized with 500 μg of DNA (83 μg per
gene/plasmid) each (one shot of 200 μl (2.5 mg/ml Diluvac)) on the
back of individual pigs). Five pigs received 800 μg of DNA (133 μg per
gene/plasmid) each, distributed into four shot sites à 200 μl (1 mg/ml
of Diluvac) on the back of individual pigs. Five pigs remained un-
vaccinated and constituted a non-immunized control group. Two weeks
after the second vaccination, all pigs were challenged intranasally (i.n.)
with 106 (TCID50)/pig of pandemic A/California/7/09 (H1N1)pdm09
applied in 1.5 ml into each nostril. All pigs were monitored daily for
clinical signs of disease or any adverse vaccination-related eﬀects.
Rectal body temperatures were recorded daily starting from two days
before challenge until the end of the experiment. Whole-blood samples
were collected from the anterior vena cava of all pigs on days −36,
−28, −21, −15, −7, 0, 7 and 13 post challenge (pc). Serum was
isolated and stored at−20 °C for subsequent examination. On days 0, 3,
5, 7, 9 and 13 pc, nasal swab samples were collected in virus transport
medium (phosphate-buﬀered saline (PBS) containing antimicrobial
drugs (100 U/mL penicillin and 0.1 mg/ml streptomycin)) from all pigs
to evaluate nasal virus shedding. Samples were stored at −80 °C until
testing. Upon termination of the experiment, on day 13 pc, the pigs
were euthanized by intravenous injection of a lethal dose of pento-
barbital followed by exsanguination. Post mortem, gross-pathological
evaluation was carried out and lung tissues (apical and middle lobes as
well as other potential lobes if evidence of gross lesions) were taken and
ﬁxed by immersion in 10% buﬀered formalin. Lung tissues were sub-
sequently embedded in paraﬃn, cut in 4 μm sections, stained with
hematoxylin-eosin stain, and slides were observed under an optical
microscope. Potential swine inﬂuenza-like lesions (broncho-interstitial
pneumonia) were scored using a previously published work (Detmer
et al., 2013).
The present study was approved by IRTA’s Ethics Committee for
Animal Experimentation and the Animal Experimentation Commission
from the Autonomous Community of Catalonia Government in com-
pliance with the Directive, UE 63/2010 and the Spanish Legislation, RD
53/2013 and the Catalan Law 5/1995 and Decree 214/1997
2.3. Inﬂuenza virus detection
A quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) assay was utilized to monitor viral loads in nasal swab
samples (day 0, 3, 5, 7, 9 and 13 pc). RNA was extracted with a MagNA
Pure LC Instrument applying the MagNA Pure LC Total Nucleic Acid
Isolation Kit (Roche diagnostics). Primers and probes for the neur-
aminidase (NA) gene of challenge virus A/California/7/09 (H1N1)
pdm09 were used to detect the challenge virus. The beta-actin house-
keeping cellular gene was used as a control for correct sampling that
should contain pig derived cell material in the swaps. Quantiﬁcation of
virus was performed by using a standard curve developed by serial
dilutions of H1N1pdm09 virus with known TCID50/ml concentration,
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included with each RT-PCR assay. Assay sensitivity for detection of
challenge virus was 15 TCID50/ml.
2.4. Enzyme-linked immunosorbent assay (ELISA)
An ELISA was conducted to measure inﬂuenza-speciﬁc IgG re-
sponses in the sera as previously described (Borggren et al., 2015). The
inﬂuenza virus protein used for coating was hemagglutinin (HA) from
A/California/04/09 (H1N1)pdm09 (Sino Biological Inc.). A horseradish
peroxidase-conjugated anti-pig-IgG antibody (AbD Serotec) followed by
TMB substrate (Kem-En-Tec Diagnostics) was used for detection. The
binding antibody titers are expressed as the reciprocal of the sample
dilution giving an optical density (OD) value of 1.0 (Bragstad et al.,
2011).
2.5. Hemagglutination inhibition (HI) assay
The HI assay was performed according to the protocols of the WHO
as previously described (Borggren et al., 2015) against virus strain A/
California/07/09 (H1N1pdm).
2.6. Microneutralization assay (MN)
Development of neutralizing antibodies was determined according
to the protocols of the WHO (Who, 2011). Viruses used were A/Cali-
fornia/07/09 (H1N1pdm), A/swine/DK/102586/2007 (H1N1) and A/
swine/DK/10496/2008 (H1N1), with 100 TCID50 as the inoculum. A/
swine/DK/102586/2007 (H1N1) and A/swine/DK/10496/2008
(H1N1) both have an avian-like H1. The MN titers is deﬁned as the
reciprocal dilution giving 50% infection inhibition and is calculated as
stated in the WHO protocol (Fenyö et al., 2009; Who, 2011) and Linear
interpolation by Reed and Muench (Reed and Muench, 1938) is used to
estimate titers if falling between two adjacent serum dilutions.
2.7. Neuraminidase inhibition (NAI) assay
The neuraminidase inhibition activity was determined using the
NA-Fluor Inﬂuenza Neuraminidase Assay kit (Life technologies) ac-
cording to the manufactures protocol, where serum and virus was al-
lowed to incubate 30 min at 37 °C before adding the NA-Fluor™
Substrate. The two virus strains, A/California/07/09 (H1N1)pdm09
and A/swine/DK/10496/2008 (H1N1), were used at 1:10 dilution,
determined to give a relative ﬂuorescence unit (RFU) within the linear
range. Serum from day−36, day 0 and day 13 pc were tested at 4-fold
dilutions starting at 1:10 up to 1:1040. Non-linear regression, with log-
transformed serum dilutions as the independent variable, was per-
formed to calculate the serum dilution that would inhibit 50% NA ac-
tivity (IC50) (Graph-Pad Prism software).
2.8. Statistical analysis
Diﬀerences between the groups were calculated using two-way
ANOVA and Dunnett’s multiple comparison test, and correlations be-
tween diﬀerent humoral immunity assays was performed using
Spearman rank correlation (GraphPad Prism v.6, GraphPad software).
3. Results
3.1. Clinical evaluation
None of the pigs showed any signs of clinical disease during the
experiment, and elevated body temperatures were not observed in any
individual animal.
3.2. Pathological evaluation
Few pigs displayed mild pulmonary cranio-ventral consolidation
(Table 1), potentially compatible with pulmonary collapse (non-virus
related) or broncho-interstitial pneumonia (virus related). Histopatho-
logical evaluation revealed that pigs receiving the highest dose of DNA
Table 1
Pathological ﬁndings.
Group Pig no. Gross-pathological lesions Scores–lungsA Swine inﬂuenza virus-like lesions
800 μg DNA/vacc. 1 No apparent lesions 0 None
2 Small consolidated areas (multifocal) in left median lobe 0 None
3 Minimal consolidation foci in the left lobe 0 None
4 No apparent lesions 0 None
5 No apparent lesions 0 None
500 μg DNA/vacc. 5 Very minimal consolidation foci right cranial lobe and left median lobe 0.5 Very mild broncho-interstitial
pneumonia
7 Small consolidated areas in right median lobe and cranial portion of right diaphragmatic
lobe
0.5 Very mild broncho-interstitial
pneumonia
8 No apparent lesions 0 None
9 Minimal consolidation areas/foci in the left medium and right cranial lobes 0.5 Very mild broncho-interstitial
pneumonia
10 No apparent lesions 0 None
No vaccine 11 Lung consolidation in right median lobe and more areas in both cranial lobes 1.5 Mild-to-moderate broncho-interstitial
pneumonia
12 Small consolidation areas in both median lobes 2 Moderate broncho-interstitial
pneumonia
13 Consolidation areas in right median and left median lobes and cranial areas of left
diaphragmatic lobe
0 None
14 Small areas of consolidation in the right apical lobe 0.5 Very mild broncho-interstitial
pneumonia
15 Very small areas of multifocal consolidation in the right apical lobe and moderate
extensive areas in the left middle lobe
1.5 Mild-to-moderate broncho-interstitial
pneumonia
A Scoring system of lung lesions by inﬂuenza in pigs according to Detmer et al. (2013) 0, No airways aﬀected; 0.5, Only a few isolated airways aﬀected; 1, Localized cluster of aﬀected
airways (in 1 or 2 lobes); 1.5, Several airways aﬀected throughout section plus minimal interstitial inﬁltrates; 2, Several airways aﬀected throughout section plus mild to moderate
interstitial inﬁltrates; 2.5, Several airways aﬀected, often severely, plus moderate interstitial and alveolar inﬁltrates; 3, Many airways aﬀected, often severely, plus moderate interstitial
and alveolar inﬁltrates.
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(800 μg) showed no lung lesions, thus no evidence of infection (5/5
scored 0). Those receiving the lower dose (500 μg) showed mild lung
pathology (in 3/5 with a score of 0.5, indicating that only a few isolated
airways were aﬀected). Four out of ﬁve pigs from the unvaccinated
group showed mild to moderate microscopic lung lesions consistent
with broncho-interstitial pneumonia (1/5 scored 0; 1/5 scored 0.5; 2/5
scored 1.5 and 1/5 scored 2). The histopathological examination re-
vealed that the lesions observed in three pigs were due to lung collapse,
not related to the inﬂuenza infection.
3.3. Antibody responses in DNA vaccinated pigs
All vaccinated pigs developed antibodies to HA, NA, M, and NP
proteins. Pigs receiving the highest dose of DNA (800 μg) developed
inﬂuenza H1pdm09-speciﬁc binding antibodies by ELISA 14 days after
the initial immunization (Fig. 1A). Following the second immunization,
the antibody titers increased and pigs receiving the lower dose of DNA
(500 μg) also developed antibodies. Control animals, not receiving any
immunization, developed a detectable HA-speciﬁc antibody response
only after viral challenge. Functionality of the HA binding antibodies
was conﬁrmed by the HI assay, demonstrating that DNA vaccination
elicited an HI antibody response against the H1N1pdm09 virus
(Fig. 1B). Both vaccinated groups showed signiﬁcantly higher HI titers
than the control group after the second immunization. After challenge,
the vaccinated animals maintained their HI titers and the control ani-
mals demonstrated a response to the challenge virus two weeks after
challenge. Binding antibody titers (ELISA) correlated with HI titers in
the vaccinated animals (P < 0.0001, R = 0.69, Spearman rank cor-
relation test).
Neutralization (Fig. 2) and neuraminidase inhibition (NAI) (Fig. 3)
assays supported the ELISA antibody response ﬁndings. Pigs given the
highest dose of DNA showed robust levels of neutralizing antibodies
against A/California/07/09 (H1N1)pdm09, A/swine/DK/102586/2007
(H1N1) and A/swine/DK/10496/2008 (H1N1). Both the high and low
dose DNA vaccinations induced NAI antibodies against both A/Cali-
fornia/07/09 (H1N1)pdm09 and A/swine/DK/10496/2008 (H1N1).
After challenge, the unvaccinated pigs developed neutralizing anti-
bodies as well as NAI antibodies, while the levels of the vaccinated
animals remained unchanged. The ELISA IgG titers correlated with the
neutralizing antibody titers in the vaccinated animals (P < 0.0001
R = 0.62, Spearman rank correlation test). The background values (day
−36) in the MN assay diﬀered in Fig. 2A–C, with a higher background
pre-vaccination to the human H1N1pdm09. This could be due to the
variation between the three diﬀerent virus isolates in this assay. The
higher neutralizing antibody titers against the human H1N1pdm09
compared to the two swine-virus isolates may be explained if
H1N1pdm09 are easier to neutralize in in vitro settings. Alternatively, it
is possible that some cross-reacting antibodies reacting with
H1N1pdm09 in the MN assay were already present in the pigs. How-
ever, all pig sera were negative pre-vaccination in ELISA detecting
binding antibodies to the H1N1pdm09. Thus, the background phe-
nomenon in the MN assay was speciﬁc for the neutralization assay.
Signiﬁcant increase from this background value could be detected in
Fig. 2A to monitor the eﬀect of the vaccinations.
3.4. Detection of virus in nasal swabs
Inﬂuenza virus RNA was detected in nasal swabs in two out of ﬁve
non-vaccinated pigs three days after challenge. Viral RNA could not be
detected in any of the 10 vaccinated pigs (< 15 TCID50/ml) (Fig. 4).
The median peak viral load was 1.95 log TCID50/ml (range 1.61–2.29
log TCID50/ml; N = 2) for non-vaccinated control pigs, and they
cleared the virus to undetectable levels at day 7 pc. Same results were
obtained using qRT-PCR for the NA, PB1 and M viral genes (data not
shown).
4. Discussion
Previously, we have shown that an optimized polyvalent inﬂuenza
DNA vaccine induced cross-reactive humoral and cellular immune re-
sponses in growing pigs after needle-less intradermal application
(Borggren et al., 2016). In the present study, we demonstrated that this
DNA vaccine provided protection against inﬂuenza challenge in pigs. In
the present study, we challenged our vaccine applying the commonly
used animal model where each individual animal are infected with a
standardized dose of challenge virus (Bragstad et al., 2013) as the al-
ternative to larger studies using contact infection models. This enabled
us to consider animal welfare recommendations by using a limited
number of experimental animals and provided the opportunity to
compare with the results of similar studies, e.g. (Bragstad et al., 2013;
Busquets et al., 2010; Gorres et al., 2011). None of the vaccinated pigs
shed virus. In addition, there was a total lack (800 μg group) or only
Fig. 1. HA-speciﬁc antibody responses following DNA vaccination and challenge. Pigs were vaccinated twice (arrows) i.d. with needle-free delivery with 800 μg (n = 5) or 500 μg
(n = 5), or not DNA vaccinated at all (n = 5). Levels of IgG in the pre- and post-challenge sera were measured by ELISA against recombinant HA (H1N1pdm09) (A). Hemagglutination
inhibition antibody responses in the pre- and post-challenge sera against H1N1pdm09 were measured (B). A Hi-titer cut-oﬀ of 20 IE/ml is indicated. Error bars indicate the mean ± SEM,
and signiﬁcant diﬀerences from the no-vaccine control group are indicated by **: p < 0.01; *: p < 0.05.
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minimal amounts (500 μg group) of microscopic lung lesions seen in the
groups receiving the DNA immunization. The humoral response after
viral challenge supported the capability of the vaccine to provide pro-
tection since the two vaccinated groups had no increase in antibody
titers after challenge, indicating the presence of functional antibodies
developed after vaccination. As observed in other inﬂuenza challenge
studies (Busquets et al., 2010; Vergara-Alert et al., 2012), the chal-
lenged pigs did not show signs of clinical disease related to inﬂuenza
infection. Gross and histopathological ﬁndings of broncho-interstitial
pneumonia, indicative of inﬂuenza virus infection, were mainly ob-
served in the unvaccinated pigs compared to the vaccinated pigs upon
challenge, further supporting the protective capabilities of the DNA
vaccine tested. The challenge virus H1N1pdm2009 turned out to con-
stitute a relatively mild challenge when looking at the relatively low
pathology scores. Yet, this virus is one of the major challenges in pro-
duction pigs in Europe, and transmission between human and pigs were
documented during the 2009 pandemic period (Nelson and Vincent,
2015; Rambaut and Holmes, 2009). Although it is the primary con-
temporary circulating inﬂuenza pathogen in industrialized pig pro-
duction there are limited vaccine possibilities available for it. There-
fore, we believe it represents a highly relevant virus for a novel vaccine
study. Importantly, the absence of clinical signs of disease during the
experiment supports previous ﬁndings (Borggren et al., 2016; Bragstad
et al., 2013) which indicated that the vaccine did not show adverse
eﬀects in vaccinated animals.
Virus shedding was detected in two out of ﬁve unvaccinated control
pigs, only. However, the development of antibody responses in all in-
dividual control pigs after challenge, demonstrated that all ﬁve control
pigs were successfully infected. The amount of virus used for inocula-
tion in the present study is comparable to that used successfully to in-
duce eﬀective infection in previous studies that also utilized intranasal
inoculation (Bragstad et al., 2013; Trebbien et al., 2013). However,
individual pig characteristics may have an eﬀect on viral shedding, as
seen also in humans (Lloyd-Smith et al., 2005; Skene et al., 2014). In
addition, it remains possible that viral shedding may have occurred on
days when nasal swab samples were not collected. Measurements of the
housekeeping gene beta-actin in parallel to H1N1pdm09 virus in the
qRT-PCR assay excluded diﬀerences in the sampled nasal swab material
and/or RNA extraction (data not shown) as a source of variations in the
nasal swab analyses.
All (5/5) non-vaccinated animals became infected, as evaluated by
several or all criteria’s: lung pathology indicative of inﬂuenza infection
in all but pig 13 (Table 1), that did however shed virus (Fig. 4) and/or
viral shedding (Fig. 4, pig 12, 13), and importantly the development of
speciﬁc antibodies in response to the challenge in all non-vaccinated
animals (5/5). This was observed in all antibody tests applied, i.e.
ELISA (Fig. 1A) and neutralizing antibody test (Fig. 2A) and HI test
(Fig. 1B) and NA inhibition test (Fig. 3). In contrast, for the high vac-
cine dose (800 μg), none (0/5) got infected, as judged by all of the same
measured criteria’s: no shedding (Fig. 4), no increase in speciﬁc binding
Fig. 2. Cross-reactive anti-H1N1 neutralizing antibody responses in vaccinated pig sera. Pigs were vaccinated twice (arrows) i.d. with needle-free delivery with 800 μg (n = 5) or 500 μg
(n = 5), or not DNA vaccinated at all (n = 5). The pre- and post-challenge pig sera were tested in a micro-neutralization (MN) assay. Neutralizing antibody titers, MN titers, were
evaluated by the capacity of the sera to prevent the infection of MDCK cells by (A) H1N1pdm09 and (B) swine 2008 H1N1 virus isolates. The MN titer was deﬁned as the reciprocal
dilution providing 50% infection inhibition, calculated with a linear interpolation method (Reed and Muench, 1938). Serum samples with a titer below the detectable limit of the assay
(lowest serum dilution tested was 1:20) were assigned a value of 10 for graphical representation and statistical analyses. Error bars indicate the mean ± SEM, and signiﬁcant diﬀerences
from the no-vaccine control group are indicated by **: p < 0.01; *: p < 0.05.
Fig. 3. Cross-reactive anti-H1N1 neuraminidase inhibition (NAI) in vaccinated pig sera. Pigs were vaccinated twice (day −36 and day −14) i.d. with needle-free delivery with 800 μg
(n = 5) or 500 μg (n = 5), or not DNA vaccinated at all (n = 5). The pre- and post-challenge pig sera were tested in an NAI assay. The NAI titers, or the serum dilutions that would inhibit
50% of neuraminidase activity (IC50), were tested against (A) H1N1pdm09 and (B) swine 2008 H1N1 isolates. Error bars indicate the mean ± SEM.
I. Karlsson et al. Veterinary Immunology and Immunopathology 195 (2018) 25–32
29
antibodies (Fig. 1A (800 μg)), no increase in functional HAI antibodies
(Fig. 1 B (800 μg)), no increase in MN titers (Fig. 2A (800 μg)), no in-
crease in NAI (Fig. 3A (800 μg)), no viral shedding (Fig. 4) and no local
lung pathology and no evidence of infection in the lung (Table 1). The
titers in the vaccinated pigs increased due to the vaccinations from day
−36 and −15 and until the day of challenge (day 0). However, from
challenge to day 7 and 13 post challenge antibody titers remained ei-
ther constant or decreased slightly (Fig. 1A + B) but in contrast to the
non-challenged pigs there was no signiﬁcant increase in the antibody
titers. The slight drop in titers day 7 post challenge (Fig. 2A) could be
due to antigen-antibody complexing or assay variation, but is not sig-
niﬁcant (Fig. 2A) and there was no change in titers from day of chal-
lenge (day 0) to day 13 post challenge, especially no signiﬁcant increase
from day of challenge as seen in the non-vaccinated pigs. Thus, 5/5
became infected in the non-vaccinated group versus 0/5 in the high
dose (800 μg) vaccine group. This was statistically signiﬁcant
(p = 0.0079, Fishers exact test).
For the low vaccine group (500 μg), we did also not ﬁnd any
shedding of virus, no increase in speciﬁc binding antibodies (ELISA
Fig. 1A (500 μg)), no increase in HI titers (Fig. 1B (500 μg)), no increase
in NAI (Fig. 3A) (500 μg), no shedding (Table 1). However, we did see
some local lung pathology in 3/5 pigs described as “very mild”, and a
slight increase in Nab (Fig. 2A) although not statistically signiﬁcant.
Thus, the lower dose vaccine seemed to provide only partial protection.
This could support a dose-related protection.
Recently, we reported an in-depth analysis of the immune response
induced by this inﬂuenza DNA vaccine in a dose-response titration
experiment, which included cross-reactive humoral and cellular dose-
dependent vaccine responses (Borggren et al., 2016). Based on results
from that study, the DNA vaccine doses used in the present study were
chosen. The current results conﬁrm and extend the prior results by
demonstrating protection against inﬂuenza challenge by the induced
response. Both doses of DNA vaccine given, 800 μg (133 μg per gene/
plasmid) and 500 μg (83 μg per gene/plasmid), induced protection
when pigs where challenged with pandemic H1N1. However, the in-
duced humoral response in the higher dose 800 μg DNA group was
broader in the in vitro neutralization analysis than the lower dose DNA
group, which neutralized a virus homologous to the vaccine only. This
observation indicates that a higher dose of vaccine is required to gain a
broader cross-reactive humoral response. Thus, it is possible that a
challenge with a more heterologous virus strain to the DNA vaccine
would diﬀerentiate protection between the two DNA doses. However, it
is promising for the DNA technology that even a low dose of 500 μg
DNA, had a protective eﬀect on a homologous virus strain, since the
general low immunogenicity of DNA vaccines in larger animals (Ferraro
et al., 2011) has previously been overcome with much larger doses of
DNA (Enama et al., 2014). Previous challenge studies by us (Bragstad
et al., 2013) and others (Gorres et al., 2011) have demonstrated pro-
tective eﬀects with DNA vaccine doses of 2000 μg and up. It is tempting
to speculate that the optimizations conducted for the DNA vaccine used
herein (Borggren et al., 2015) have improved the immunogenicity in
such a way that the potential to deliver substantially lower doses of
DNA in the future seems realistic. This would be a central aspect for the
practical use of a DNA vaccine in swine herds where vaccine costs are of
utmost importance.
The demonstrated DNA dose-dependence was also reﬂected in the
induced humoral response after immunizations. The higher DNA dose
already demonstrated ELISA binding and HI titers after the ﬁrst im-
munization, which were boosted after the second one. In contrast, the
lower dose of 500 μg DNA seems to require two immunizations to in-
duce a measurable humoral response. As for the commercial protein-
based inﬂuenza vaccines the protective eﬀect of the DNA most likely
includes the vaccine-induced H1N1pdm09 IgG antibodies (Kutzler and
Weiner, 2008; Pica and Palese, 2013; Van Reeth and Ma, 2013). In
addition to the antibodies to HA, there were also antibodies to the NA
surface protein, which neutralized the NA activity in the NAI assay. The
relative or combined role of neutralizing anti-HA and anti-NA anti-
bodies may be important (Pica and Palese, 2013) but will require fur-
ther experiments to be deﬁned.
Other potential mechanisms may be involved using DNA vaccines
instead of protein vaccines, such as cellular immunity e.g. towards the
more conserved antigens nucleoprotein (NP) and matrix (M) (Bragstad
et al., 2011; Gorres et al., 2011; Liu, 2011; Sridhar et al., 2013). The
cellular immunity was not assessed in this study, since our recent
evaluation of vaccine-induced immunity already clearly demonstrated a
strong cell-mediated immune response after DNA immunization
(Borggren et al., 2016), including both IFN-γ-producing T cells against
several diﬀerent inﬂuenza speciﬁc proteins and functional proliferation
following inﬂuenza stimulation. In addition, we have previously de-
monstrated protection against inﬂuenza induced by NP and M genes of
1918 origin alone in ferrets (Bragstad et al., 2011). However, in vivo
expression of NP, M1 and M2 was conﬁrmed by measuring antibody
induction to these proteins in ELISA (data not shown).
Future studies including larger experiments using also contact-in-
fected pigs are needed to address the potential impact of cross-reactive
protection against infection of also other inﬂuenza strains. We have
previously reported DNA-induced protective cross-reactive antibodies
between diﬀerent H3N2 inﬂuenza strains in pigs (Bragstad et al., 2013)
Fig. 4. Protective eﬃcacy of the inﬂuenza DNA vaccine. Vaccinated and control animals were challenged with pandemic H1N1 A/California/07/2009. Post-challenge viral loads were
assessed for up to 13 days in nasal swabs. Data are expressed as the mean log10 virus titer ± SEM.
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and thus speculate that the present optimized DNA vaccine has the
potential to induce broad protection.
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